文献速递妇科

NovaSure子宫内膜消融术远期失败的预测因素

Predictors of Long-Term NovaSure Endometrial Ablation Failure.
PubMed 文献 · J Minim Invasive Gynecol · 2018-03-14

这项回顾性多中心队列研究纳入2008至2014年间接受NovaSure子宫内膜消融术的486例月经过多患者,中位随访45个月,19.3%需二次治疗。多因素分析显示年轻、绝育史、痛经及超声见肌壁间肌瘤为独立预测因素,术前宫腔镜似为保护因素。

要点

  • 中位随访45个月,19.3%(94例)需二次治疗,视为NovaSure失败。
  • 年轻(p=.019)、绝育史(p=.002)、痛经(p<.001)、肌壁间肌瘤(p=.005)为独立预测因素。
  • 术前宫腔镜似为保护因素(p=.001)。

核心结论

  • 中位随访45个月内19.3%的患者需二次治疗,识别消融失败的特定预测因素对术前咨询和患者选择重要。

研究设计与样本

  • 回顾性多中心队列研究(加拿大工作组分类II-2),纳入1所大学医院和1所大型教学医院2008至2014年间接受NovaSure子宫内膜消融术的486例月经过多患者。

主要发现

  • 中位随访45个月,19.3%(n=94)需二次治疗,视为NovaSure失败。
  • 多因素logistic回归显示年轻(p=.019)、绝育史(p=.002)、痛经(p<.001)及经阴道超声见肌壁间肌瘤(p=.005)为NovaSure消融失败的独立预测因素。
  • 术前宫腔镜似为保护因素(p=.001)。

临床怎么用

  • 原文结论认为识别消融失败的特定预测因素对术前咨询和患者选择重要,在个性化医疗时代医生和患者宜选择个体成功率最高的治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Endometrial ablation using the NovaSure system (Hologic Inc., Marlborough, MA) is 1 of the treatment options for heavy menstrual bleeding (HMB), which has a reported success rate of 81% to 90%. We aimed to identify predictors for NovaSure endometrial ablation failure. This will contribute to a more effective and individualized preoperative counseling. DESIGN: A retrospective multicenter cohort study (Canadian Task Force classification II-2). SETTING: One university hospital and 1 large teaching hospital. PATIENTS: Four hundred eighty-six patients with HMB who had undergone NovaSure endometrial ablation between 2008 and 2014. INTERVENTIONS: The NovaSure endometrial ablation system for patients with HMB. MEASUREMENTS AND MAIN RESULTS: In total, the required characteristics of 486 patients were collected and analyzed. With a median follow-up of 45 months, 19.3% (n = 94) required a secondary treatment and thus were considered NovaSure failures. Multivariate logistic regression analysis showed that younger age (p = .019), a history of sterilization (p = .002), the presence of dysmenorrhea (p < .001) and the presence of an intramural leiomyoma on transvaginal sonography (p = .005) were independent predictors of NovaSure ablation failure. Preoperative hysteroscopy appeared to be a protective factor (p = .001). CONCLUSION: Within a median follow-up of 45 months, 19.3% of patients required a secondary treatment. Identification of specific predictive factors for endometrial ablation failure is important in preoperative counseling and patient selection. In the current era of personalized medicine, doctors and patients will ideally choose the therapy that results in the highest chance of success in the individual case.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Lybol C, van der Coelen S, Hamelink A, et al. Predictors of Long-Term NovaSure Endometrial Ablation Failure. J Minim Invasive Gynecol. 2018. PMID: 29550389. doi:10.1016/j.jmig.2018.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。